Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

mTOR inhibitor (protein kinase inhibitor); antineoplastic agent

Everolimus

Afinitor

Dosage form
Tablet
Available strengths
2.5 mg, 5 mg, 10 mg (tablets); 2 mg, 3 mg, 5 mg (tablets for oral suspension)
Drug class
mTOR inhibitor (protein kinase inhibitor); antineoplastic agent
Common brand
Afinitor

Clinical overview. Everolimus (Afinitor, Afinitor Disperz) is an oral mTOR inhibitor used to treat certain advanced cancers, including some breast, neuroendocrine, and kidney cancers, as well as tumours and seizures linked to tuberous sclerosis complex. It works by blocking a cell-signalling pathway that cancer and TSC-related cells depend on to grow. Because it also affects the immune system and metabolism, everolimus carries risks of serious infections, lung inflammation, and changes in blood sugar and cholesterol, and it interacts with many common medicines through the liver's CYP3A4 enzyme system.

Indication

Common therapeutic uses

  • Everolimus (Afinitor) is used with exemestane to treat hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women whose cancer has progressed after treatment with letrozole or anastrozole.
  • Everolimus is used to treat advanced neuroendocrine tumours of the pancreas that cannot be surgically removed or have spread.
  • Everolimus is used to treat advanced, well-differentiated neuroendocrine tumours of the gastrointestinal tract or lung that have progressed.
  • Everolimus is used to treat advanced kidney cancer (renal cell carcinoma) after other targeted therapies have stopped working.
  • Everolimus is used to treat kidney angiomyolipoma (a type of benign tumour) associated with tuberous sclerosis complex (TSC) that does not require immediate surgery.
  • Everolimus (Afinitor) and its oral suspension form (Afinitor Disperz) are both used to treat subependymal giant cell astrocytoma (SEGA), a brain tumour associated with TSC.
  • Afinitor Disperz specifically is also used as an add-on treatment for seizures associated with TSC that are not well controlled with other therapies.
  • Everolimus is not recommended for functional carcinoid tumours, since a clinical trial did not show a clear benefit in this specific tumour type.

Pregnancy

Risk assessment and monitoring considerations

  • Everolimus can cause harm to a developing baby, based on animal studies showing pregnancy loss and toxicity to the fetus at doses lower than those used in humans.
  • Women of childbearing potential should use highly effective contraception during treatment and for up to 8 weeks after the last dose.

Breastfeeding

Infant exposure considerations

  • It is not known whether everolimus passes into human breast milk, but animal studies show it does pass into milk, so breastfeeding should be avoided during treatment and for 2 weeks after the last dose.

Geriatrics

Dosing and tolerability considerations

  • No dosage adjustment is required for everolimus based on age alone.
  • Older adults (65 years and over) treated for advanced breast cancer had a higher rate of death within 28 days of the last dose and more treatment discontinuations due to side effects than younger patients, so closer monitoring is recommended in this group.

Pediatrics

Use in children and adolescents

  • Everolimus is authorized for children over 1 year of age with SEGA associated with TSC, though data are limited for children 1 to 3 years old.
  • Afinitor Disperz is authorized for children 2 years and older with seizures associated with TSC, but has not been studied in children under 2 years old.
  • Children under 6 years of age with TSC had a notably higher rate of severe infections during everolimus treatment compared with older children and adults.
  • Everolimus is not authorized for pediatric use in breast cancer, neuroendocrine tumours, kidney cancer, or renal angiomyolipoma associated with TSC.

Dosage & Administration

Practical dosing and administration

  • For breast cancer, neuroendocrine tumours, kidney cancer, and renal angiomyolipoma associated with TSC, the recommended dose is 10 mg taken by mouth once daily.
  • For SEGA associated with TSC, dosing is individualized based on body surface area, then adjusted using blood level (trough concentration) monitoring to reach a target range.
  • For seizures associated with TSC, the starting dose of Afinitor Disperz depends on the patient's age and whether they are taking an interacting seizure medicine, then titrated using blood level monitoring.
  • Afinitor tablets and Afinitor Disperz oral suspension are not interchangeable and should not be combined to make up a dose; only one form should be used consistently for a given indication.
  • Afinitor Disperz tablets must be dispersed in water using an oral syringe or a small drinking glass and taken as a suspension; they should never be swallowed whole, chewed, or crushed.
  • The dose should be reduced by about half if a moderate CYP3A4 or P-glycoprotein inhibitor must be co-administered, and strong inhibitors should be avoided altogether.
  • The dose should be reduced in patients with mild, moderate, or severe liver impairment, using specific dose tables based on Child-Pugh class and indication.
  • No dose adjustment is needed for kidney impairment, since everolimus is only minimally cleared by the kidneys.
  • If a dose is missed by up to 6 hours from its usual time, it can still be taken; beyond 6 hours, that day's dose should be skipped and the next dose taken as usual the following day, without doubling up.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Human experience with everolimus overdose is very limited; single doses up to seven times the usual daily dose have been tolerated acceptably in reported cases.
  • There is no specific treatment for everolimus overdose.
  • Management of overdose involves general supportive care, including frequent monitoring of vital signs and close observation.

Common side effects

Frequently reported tolerability concerns

  • Mouth sores (stomatitis) are very common and often occur within the first 8 weeks of treatment.
  • Rash is common.
  • Diarrhea is common.
  • Fatigue is common.
  • Decreased appetite is common.
  • Swelling (edema), including in the legs, is common.
  • Nausea is common.
  • Fever is common.
  • Headache is common.
  • Cough is common.
  • High blood sugar (hyperglycemia) is common.
  • High cholesterol or triglycerides (hyperlipidemia) is common.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Non-infectious lung inflammation (pneumonitis) can occur and has, in rare cases, been fatal.
  • Serious infections, including fungal, bacterial, and viral infections, can occur because everolimus suppresses the immune system; some cases have been fatal.
  • Kidney failure, including acute kidney failure, has occurred, with some fatal cases.
  • Serious bleeding (hemorrhage), including in the digestive tract, lungs, or brain, has been reported, with some fatal cases.
  • Severe hypersensitivity reactions, including anaphylaxis and swelling of the airway or tongue (angioedema), can occur, and the risk is higher in patients also taking an ACE inhibitor blood pressure medicine.
  • Unconfirmed reports of muscle breakdown (rhabdomyolysis) have occurred, especially in patients also taking a statin.
  • Blood clots, including deep vein thrombosis and pulmonary embolism, have been reported.
  • Low blood counts, including low platelets, low white blood cells, and low red blood cells, can occur.
  • New-onset type 2 diabetes has occurred with everolimus treatment.
  • Delayed wound healing is a known effect of this class of drugs, so caution is needed around the time of surgery.
  • Menstrual periods can stop (amenorrhea) in women taking everolimus, and both female and male fertility may be affected.
  • Urgent medical attention should be sought for new or worsening shortness of breath, cough, or chest pain; signs of a serious infection such as high fever; unusual bleeding; or symptoms of a severe allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients taking an ACE inhibitor blood pressure medicine, due to an increased risk of angioedema.
  • Use with caution in patients taking a statin medicine, due to a possible increased risk of muscle breakdown.
  • Use with caution in patients with pre-existing lung disease, given the risk of non-infectious pneumonitis.
  • Use with caution in patients with a history of bleeding disorders or who are taking medicines that affect platelet function or increase bleeding risk.
  • Use with caution in patients undergoing surgery, since wound healing can be impaired.
  • Use with caution in patients receiving radiation therapy before, during, or after everolimus, due to the risk of radiation sensitization or radiation recall reactions.
  • Use with caution in patients with diabetes or risk factors for diabetes, since everolimus can raise blood sugar.
  • Use with caution in patients with high cholesterol, since everolimus can worsen lipid levels.
  • Avoid live vaccines during treatment, since everolimus suppresses the immune system.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to everolimus, other rapamycin derivatives (such as sirolimus or temsirolimus), or to any ingredient in the formulation.
  • Contraindicated for the treatment of seizures in patients without a definite diagnosis of tuberous sclerosis complex.

Drug interactions

Clinically relevant combinations

  • Strong CYP3A4 or P-glycoprotein inhibitors, such as ketoconazole, itraconazole, clarithromycin, and ritonavir, substantially raise everolimus blood levels and should be avoided.
  • Moderate CYP3A4 or P-glycoprotein inhibitors, such as erythromycin, verapamil, fluconazole, diltiazem, and cyclosporine, raise everolimus blood levels and require dose reduction and caution.
  • Strong CYP3A4 or P-glycoprotein inducers, such as rifampin, carbamazepine, phenobarbital, and phenytoin, lower everolimus blood levels and reduce its effectiveness; combined use should generally be avoided or the dose adjusted.
  • St. John's Wort can lower everolimus blood levels and should be avoided.
  • Grapefruit, grapefruit juice, star fruit, and Seville oranges can raise everolimus blood levels and should be avoided during treatment.
  • Statins such as atorvastatin, simvastatin, and pravastatin do not show clinically significant pharmacokinetic interactions, but the combination raises the risk of muscle breakdown and should be used with caution.
  • Everolimus can raise blood levels of midazolam and other CYP3A4 substrate drugs with a narrow therapeutic range, requiring caution.
  • Everolimus can raise pre-dose blood levels of certain seizure medicines, including carbamazepine and clobazam, which may need monitoring.
  • ACE inhibitor blood pressure medicines taken together with everolimus increase the risk of angioedema.
  • Everolimus may reduce the effectiveness of vaccines, and live vaccines should be avoided during treatment.

Food interactions

Meal-related administration

  • Everolimus and Afinitor Disperz should be taken consistently either always with food or always without food, at the same time every day, rather than switching between the two approaches.
  • Grapefruit and grapefruit juice can raise everolimus blood levels and should be avoided regardless of the with-food or without-food approach chosen.

Time of administration

Practical scheduling

  • Everolimus is taken by mouth once daily, preferably in the morning, at the same time each day, either consistently with food or consistently without food.

Storage

Product handling

  • Store everolimus tablets and tablets for oral suspension at room temperature (15°C to 30°C), in the original package, protected from light and moisture.
  • Keep out of the reach of children and pets.
  • Prepared Afinitor Disperz suspension should be administered right after mixing and discarded if not given within 60 minutes.

Patient take-away

Key counselling points for a quick closing summary

  • Everolimus is a once-daily oral cancer or TSC medicine that must be taken at the same time and in the same way (with or without food) every day.
  • Report any new cough, shortness of breath, or fever promptly, since everolimus can cause serious lung or immune system effects.
  • Avoid grapefruit products and tell your healthcare provider about all other medicines, since many can raise or lower everolimus levels in your blood.
  • Mouth sores are common; ask your care team about mouthwashes to use and ones to avoid.
  • Effective contraception is needed during treatment for women who could become pregnant.

References

Source material and product information

  1. Health Canada Product Monograph — Everolimus

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.